Aims: An audit was conducted to evaluate the demography, clinical presentation,
management, and outcome of MTC in a tertiary care center in South India. Settings and …

Background Thyroid cancer (TC) comprises 1% of all carcinomas and is the most common
malignancy of the endocrine system. The disease is more common in women, with its peak …

Objective: Medullary thyroid carcinoma (MTC) is a rare thyroid malignancy originating from
parafollicular C-cells with the potential for aggressive behavior. The extent of lymph node …

Objective Medullary thyroid carcinoma (MTC) has varying clinical course. We assessed
trends in MTC presentation during the last 34 years. Design Retrospective study. Methods …

За последние 4 года ведущие эндокринологические сообщества разных стран
выпустили рекомендации, посвященные диагностике и лечению медуллярного рака …

Objective Calcitonin (Ct)-negative medullary thyroid carcinoma (MTC) is a rare
neuroendocrine tumor. This study aimed to clarify its incidence, clinicopathologic …

Medullary thyroid cancer (MTC) arises from parafollicular C cells and is an elusive tumor to
image. It occurs as a sporadic neoplasm in 70–80% of cases and is hereditary in 20–30 …

Mechanisms of endocrine secretory granule (SG) formation in thyroid C cells and medullary
thyroid cancer (MTC) cells have not been fully elucidated. Here we directly demonstrated …

Medullary thyroid carcinoma (MTC) accounts for only 2–5% of all thyroid malignancies.
Clinical and pathological characteristics alone may suffice to predict outcomes, but unstable …

Background Glucagon‐like peptide‐1 receptor agonists, such as dulaglutide, exenatide and
liraglutide, are approved to treat Type 2 diabetes mellitus. Although these drugs provide …